Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV

Stopped early

Conditions studied: HIV Infections, Hepatitis C Virus

In brief

This pilot study aims to study gut B cells in HCV+HIV+, HCV+HIV-, HCV-HIV+, and HCV-HIV- volunteers. Volunteers will undergo a screening blood draw and flexible sigmoidoscopy with biopsy.

Key facts

Study ID

NCT01040039

Run by

Rockefeller University

People needed

20

Starts

2009-11-01

Expected to finish

2011-09-01

Last updated by the study team

2013-05-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Between 18 and 75 years of age.
• Ability to give informed consent.
• Platelets greater than 70,000/mm3.
• Hb at least 9.5 g/dl.
• INR < 1.5.

You may not qualify if…

• Decompensated cirrhosis.
• Serious uncontrolled medical illness.
• Ingestion of Aspirin within 72 hours of sigmoidoscopy
• Ingestion of non aspirin NSAIDS within 8 hours of sigmoidoscopy
• Receipt of immune modulators or suppressors within 30 days prior to study entry, including, but not limited to, interferons and thalidomide.
• Psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements.
• Alcohol or drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
• Medical illness requiring prescribed Aspirin or NSAIDs.

Where it is running

• Rockefeller University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.